| Studie - kortnavn | Tittel | Status |
| PROMO | En fase II studie med pembrolizumab (MK-3475) for pasienter med osteosarkom som ikke er tilgjengelig for kurativ kirurgi | Pågående studie sammen med Italian Sarcoma Group |
| A6181196 | A phase I/II study of Sunitinib in young patients with advanced gastrointestinal stromal tumor | Stengt. Ingen pasienter inkludert. |
| Euroboss | A European treatment protocol for bone sarcoma in patients older than 40 years | Stengt for inklusjon. Oppfølging pågår |
| SSG XX | A Scandinavian Sarcoma group treatm.protocol for adult pas with non-met high-risk STS of extremities and trunk wall | Stengt for inklusjon. Oppfølging pågår |
| STRASS | A phase III randomised study of pre-operativ radiation plus surgery versus surgery alone for patients with retroperitoneal sarcomas | Stengt for inklusjon. Oppfølging pågår |
| SSG XXII | Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk of reccurence | Pågående studie sammen med Skandinavia og Europeiske land |
| rEECur | International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma | Pågående studie sammen med Skandinavia og Europeiske land |
| EURAMOS | A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy | Stengt for inklusjon. Oppfølging pågår. |
| CREATE | Cross-tumoral phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET ("CREATE") | Stengt for inklusjon. Oppfølging pågår. |
| EpSSG NRSTS 2005 | A protocol for localized non-rhabdomyosarcom soft tissue sarcoma | Stengt for inklusjon. |
| EpSSG RMS 2005 | A protocol for non metastatic rhadomyosarcoma | Stengt for inklusjon. |
| ALT GIST | A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib treatment of advanced gastrointestinal stromal tumour (GIST) | Stengt for inklusjon. Oppfølging pågår. |
| DOREMY | DOse REduction of preoperative radiotherapy in MYxoid liposarcomas | Åpen for inklusjon. Studie sammen med Nederland, England og skandinaviske land |
| SSG XVIII | Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imantinib mesylate of operable GIST with a high risk for recurrence: A randomized phase III study | Stengt for inklusjon. Oppfølging pågår. |
| SSG XIII | A Scandinavian Sarcoma Group treatment protocol for adult patients with high-risk STS of exstremities and trunk wall | Stengt for inklusjon. Oppfølging pågår. |
| MEMOS | A mechanistic study of Mifamurtide (MTP-PE) in patients with metastatic and/or reccurent Osteosarcoma | Stengt for inklusjon. Ingen oppfølging |
| STOP-GIST | Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment | Åpen for inklusjon. Studie sammen med andre sentre SSG sentre. |
| NBTXR3 | A multicenter randomized, open-label phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall | Studien er stengt. |
| ARO-012 | A randomized, double-blind, placebo-controlled, multicenter, trial of Crenolanib in subjects with advanced or metastatic Gastrointestinal Stromal Tumor with a D842V mutation in the PDGFRA gene | Åpen for inklusjon. |
| ISG/SSG III | An Italian-Scandinavian treatment protocol, non-metastatic Ewing`s family tumors | Stengt for inklusjon. Oppfølging pågår. |
| SACRO | SAcral Chordoma: a Randomized & Observational study on surgery versus definitive radiation therapy in primary localized disease | Åpnes i 2018 |